Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford-led National Consortium of Intelligent Medical Imaging (NCIMI) in the UK is collaborating with GE Healthcare to develop and test algorithms to aid in the diagnosis and management of COVID-19 pneumonia.

The program will focus on developing, enhancing and testing potential algorithms to help diagnose COVID-19 pneumonia, predict which patients will develop severe respiratory distress - a key cause of mortality in patients who develop COVID-19 pneumonia - and which patients might develop longer term lung function problems, even when they recover from respiratory distress.

At present, clinicians cannot easily predict which patients who test positive for COVID-19 will deteriorate and require hospital admission for oxygen and possible ventilation. Nor is it clear which patients will suffer long-term consequences from the lung damage from COVID-19 pneumonia. The teams aim to develop algorithms incorporating data from thousands of patients medical imaging, laboratory and clinical observations to provide both a quicker diagnosis and a prediction of how a patient may progress and recover.

Currently, some patients admitted to hospital do not see a worsening of their symptoms, while others who appear stable can deteriorate rapidly. Identification of those patients at highest risk of deterioration and long-term lung function problems may help physicians and caregivers to accelerate intensive support. It may also allow those with lower risk to be monitored in a suitably safe environment, potentially including the patient’s home. GE Healthcare and NCIMI aim to develop tools to help in the management of these COVID-19 patients from triage to acute monitoring, interventions, to discharge and those requiring follow-up after recovery.

Read more on the University of Oxford website

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.